person
as of 2026-07-01Ginger Nicol, MD
ORCID 0000-0001-5823-6129
at a glance
Roles: Principal Investigator, Author
KOL signal score 2
1 publications · 0 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Washington University School of Medicine
Roles
Principal Investigator, Author
KOL signal
2
Publications
1 (0 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
2
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
NCT02717130—Terminated
Effects of Antipsychotic Medications on Energy Intake and Expenditure
NCT00836251—Completed
Publications & congress
1
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug